|Accession Number||DB00225 (APRD00990)|
Gadodiamide is a gadolinium based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan.
|Approved Prescription Products|
|Approved Generic Prescription Products||Not Available|
|Approved Over the Counter Products||Not Available|
|Unapproved/Other Products||Not Available|
|International Brands||Not Available|
|Brand mixtures||Not Available|
|Weight||Average: 573.66 |
For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
|Structured Indications||Not Available|
|Mechanism of action|
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.
|Volume of distribution|
|Protein binding||Not Available|
There is no detectable biotransformation or decomposition of gadodiamide.
|Route of elimination|
Gadodiamide is eliminated primarily in the urine.
Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.
|Pharmacogenomic Effects/ADRs||Not Available|
|Drug Interactions||Not Available|
|Food Interactions||Not Available|
|Synthesis Reference||Not Available|
|General References||Not Available|
|ATC Codes||V08CA03 — Gadodiamide|
|PDB Entries||Not Available|
|FDA label||Not Available|
|MSDS||Download (56.3 KB)|
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
|Experimental Properties||Not Available|
|Predicted ADMET features|
|Mass Spec (NIST)||Not Available|
|Description||This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.|
|Super Class||Organic acids and derivatives|
|Class||Carboxylic acids and derivatives|
|Sub Class||Amino acids, peptides, and analogues|
|Direct Parent||Alpha amino acid amides|
|Alternative Parents||Alpha amino acids / Tricarboxylic acids and derivatives / Trialkylamines / Secondary carboxylic acid amides / Carboxylic acid salts / Amino acids / Carboxylic acids / Organic zwitterions / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds|
|Substituents||Alpha-amino acid amide / Alpha-amino acid / Tricarboxylic acid or derivatives / Carboxamide group / Carboxylic acid salt / Secondary carboxylic acid amide / Tertiary amine / Tertiary aliphatic amine / Amino acid / Carboxylic acid/ Amine / Organic oxygen compound / Organooxygen compound / Organonitrogen compound / Organic nitrogen compound / Carbonyl group / Organic oxide / Organic zwitterion / Organic salt / Hydrocarbon derivative / Aliphatic acyclic compound|
|Molecular Framework||Aliphatic acyclic compounds|
|External Descriptors||gadolinium coordination entity (CHEBI:37333 )|